Heart-on-a-Chip Technology Predicts Preclinical Systolic and Diastolic in vivo Observations for Novel Cardiac Drug in Development
November 18, 2019
Featured
NEW YORK, NY (Newswire.com)—TARA Biosystems, Inc. today reported in vivo and in vitro functional data from a study of …
TARA Biosystems Launches Cardiotype.Ca™ Cardiac Calcium Signaling Assay: In Vitro Assay Accelerates Drug Development in Human-Relevant Heart Models
September 23, 2019
News
NEW YORK, NY (Newswire.com) - TARA Biosystems, Inc. launched Cardiotype.Ca™, its in vitro system for assessing cardiac calcium signaling. The new assay can be used independently or in combination with TARA’s <…
Heart-on-a-Chip Mimics Drug Response Seen in Humans: In Vitro Approach Provides Predictive Platform for Human-Based Drug Discovery
August 6, 2019
News
NEW YORK, N.Y. (Newswire.com)— Researchers from TARA Biosystems, Inc. and GlaxoSmithKline (GSK) today published data demonstrating that TARA’s engineered heart-on-a-chip system replicated drug responses found in adult humans. The …
TARA Secures Exclusive Worldwide License to Columbia University Intellectual Property relating to Engineered Human Cardiac Tissues
May 28, 2019
News
NEW YORK, N.Y. (Newswire.com)— TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the execution of an exclusive worldwide license agreement with Columbia …
TARA Announces Issuance of US Patent for Biowire™ II Platform
May 14, 2019
News
New York, NY, (Newswire.com) - TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced that the United States Patent and Trademark Office (USPTO) has …
TARA presents at WuXi Healthcare Forum in Shanghai
March 5, 2019
News
TARA presents today at the WuXi Healthcare Forum in Shanghai. The forum brings together 1000+ innovators, entrepreneurs, clinicians, and investors from around the world that are shaping the future of healthcare.
TARA Biosystems Biowire™ II Heart-on-a-Chip Platform Published in CELL
January 24, 2019
News
NEW YORK, (Newswire.com) TARA Biosystems, Inc., a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the first peer-reviewed publication of its Biowire™ II platform by a team of …
TARA Biosystems and Insilico Medicine Announce Drug Discovery Collaboration for Cardiac Disease
January 7, 2019
News
New York – TARA Biosystems, Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and risk assessment applications and Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines for age-related diseases, announced today the launch of a collaboration to discover and develop novel therapies for …
TARA Launches Cardiotype.Fo, Best-In-Class Assay for Cardiac Contractility
September 27, 2018
News
New York, (Newswire.com) - TARA Biosystems, Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and development applications announced today the launch of Cardiotype.Fo, the best-in-class in vitro system for assessment of cardiac …
Frost & Sullivan Recognizes TARA With 2018 North American Technology Innovation Award
September 25, 2018
News
TARA has received Frost & Sullivan’s 2018 North American Technology Innovation Award for our Biowire™ II platform! This award recognizes companies that develop innovative products with rapid market adoption. In addition, it is part of a broader set of Frost & Sullivan’s Best Practices awards presented to companies …